Zusammenfassung
Das Auftreten von Toxizität und das Vorliegen anderer medizinischer Erkrankungen, die die Lebenserwartung bestimmen, sind die Hauptgründe, bei alten Patienten mit Krebserkrankungen keine Standardtherapie einzusetzen. Mit Alter und Komorbidität assoziierte Veränderungen der Organfunktion können zu einer Veränderung pharmakokinetischer Parameter führen und die Therapiefähigkeit beeinflussen. Therapiefähigkeit ist ein in der Fachliteratur nicht klar definierter Terminus. Neben der erwarteten Toxizität hängt sie vom Therapieziel und anderen altersassoziierten Parametern ab, die am besten durch ein umfassendes geriatrisches Assessment erfasst werden.
Abstract
Both the occurrence of toxicity and the presence of other medical disorders determining patient life-expectancy are major reasons not to apply standard oncological treatment in elderly cancer patients. Age- and comorbidity-associated changes in organ function will affect the pharmacokinetics of anticancer drugs and may thus impact treatment selection and dosing. Fitness for treatment is not a well-defined term in cancer literature. Besides the expected toxicity fitness for treatment depends on the aims of treatment and other age-associated variables which are best evaluated by a comprehensive geriatric assessment.
This is a preview of subscription content, log in via an institution to check access.
Literatur
Smith BD, Smith GL, Hurria A et al (2009) Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol 27(17):2758–2765
Wildiers H (2007) Mastering chemotherapy dose reduction in elderly cancer patients. Eur J Cancer 43(15):2235–2241
Wedding U (2010) Chances and limitations of chemotherapy in elderly patients. Internist (Berl) 51(3):402, 404–406, 408–409
Hurria A, Brogan K, Panageas KS et al (2005) Effect of creatinine clearance on patterns of toxicity in older patients receiving adjuvant chemotherapy for breast cancer. Drugs Aging 22(9):785–791
Gourgou-Bourgade S, Bascoul-Mollevi C, Desseigne F et al (2012) Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial. J Clin Oncol 31(1):23–29
Takimoto CH (2009) Maximum tolerated dose: clinical endpoint for a bygone era? Target Oncol 4(2):143–147
Lee SM, Khan I, Upadhyay S et al (2012) First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 13(11):1161–1170
Aranda E, Manzano JL, Rivera F et al (2012) Phase II open-label study of erlotinib in combination with gemcitabine in unresectable and/or metastatic adenocarcinoma of the pancreas: relationship between skin rash and survival (Pantar study). Ann Oncol 23(7):1919–1925
Banerji U, Ashley S, Coward J et al (2006) The association of chemotherapy induced neutropenia on treatment outcomes in small cell lung cancer. Lung Cancer 54(3):371–377
Pallis AG, Ring A, Fortpied C et al (2010) EORTC workshop on clinical trial methodology in older individuals with a diagnosis of solid tumors. Ann Oncol 22(8):1922–1926
Wedding U, Merkel U, Farker K et al (2003) Oncologic pharmacotherapy of elderly patients. Internist (Berl) 44(8):977–985
Hurria A, Lichtman SM (2007) Pharmacokinetics of chemotherapy in the older patient. Cancer Control 14(1):32–43
Launay-Vacher V, Chatelut E, Lichtman SM et al (2007) Renal insufficiency in elderly cancer patients: International Society of Geriatric Oncology clinical practice recommendations. Ann Oncol 18(8):1314–1321
Faluyi OO, Masinghe SP, Hayward RL et al (2012) Accuracy of GFR estimation by the Cockroft and Gault, MDRD, and Wright equations in oncology patients with renal impairment. Med Oncol 29(2):755–760
Lichtman SM, Wildiers H, Launay-Vacher V et al (2007) International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. Eur J Cancer 43(1):14–34
Janus N, Launay-Vacher V, Byloos E et al (2010) Cancer and renal insufficiency results of the BIRMA study. Br J Cancer 103(12):1815–1821
King S, Forbes K, Hanks GW et al (2011) A systematic review of the use of opioid medication for those with moderate to severe cancer pain and renal impairment: an European Palliative Care Research Collaborative opioid guidelines project. Palliat Med 25(5):525–552
Pergolizzi J, Boger RH, Budd K et al (2008) Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract 8(4):287–313
Terpos E, Sezer O, Croucher PI et al (2009) The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. Ann Oncol 20(8):1303–1317
Launay-Vacher V, Spano JP, Janus N et al (2009) Renal insufficiency and anticancer drugs in elderly cancer patients: a subgroup analysis of the IRMA study. Crit Rev Oncol Hematol 70(2):124–133
Janus N, Launay-Vacher V, Thyss A et al (2013) Management of anticancer treatment in patients under chronic dialysis: results of the multicentric CANDY (CANcer and DialYsis) study. Ann Oncol 24(2):501–507
Extermann M, Boler I, Reich RR et al (2012) Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-age Patients (CRASH) score. Cancer 118(13):3377–3386
Hurria A, Togawa K, Mohile SG et al (2011) Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol 29(25):3457–3465
Interessenkonflikt
Keine Angaben.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wedding, U., Bokemeyer, C. Pharmakokinetische Parameter. Forum 28, 164–169 (2013). https://doi.org/10.1007/s12312-013-0941-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12312-013-0941-x